Padmanabh Bhatt Sells 7,250 Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh Bhatt sold 7,250 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $49.60, for a total value of $359,600.00. Following the completion of the sale, the vice president owned 17,044 shares of the company’s stock, valued at approximately $845,382.40. The trade was a 29.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Supernus Pharmaceuticals Trading Down 0.9%

SUPN opened at $48.84 on Friday. Supernus Pharmaceuticals, Inc. has a 1-year low of $29.16 and a 1-year high of $59.68. The company has a fifty day moving average price of $51.18 and a two-hundred day moving average price of $49.17. The company has a market cap of $2.81 billion, a P/E ratio of -71.82, a price-to-earnings-growth ratio of 1.53 and a beta of 0.70.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Rubric Capital Management LP bought a new position in shares of Supernus Pharmaceuticals in the second quarter worth $21,908,000. Woodline Partners LP raised its holdings in shares of Supernus Pharmaceuticals by 63.5% in the 3rd quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock valued at $60,398,000 after acquiring an additional 490,835 shares in the last quarter. Bank of America Corp DE lifted its position in Supernus Pharmaceuticals by 67.1% during the third quarter. Bank of America Corp DE now owns 842,890 shares of the specialty pharmaceutical company’s stock valued at $40,282,000 after purchasing an additional 338,584 shares during the last quarter. Morgan Stanley grew its position in Supernus Pharmaceuticals by 42.9% in the fourth quarter. Morgan Stanley now owns 1,079,471 shares of the specialty pharmaceutical company’s stock worth $53,650,000 after acquiring an additional 324,154 shares in the last quarter. Finally, UBS Group AG raised its holdings in shares of Supernus Pharmaceuticals by 137.6% during the 3rd quarter. UBS Group AG now owns 540,123 shares of the specialty pharmaceutical company’s stock valued at $25,812,000 after buying an additional 312,775 shares in the last quarter.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Wall Street Zen cut Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Sunday, March 8th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, December 29th. Craig Hallum set a $65.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, February 25th. Zacks Research lowered shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 29th. Finally, Stifel Nicolaus boosted their target price on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a research note on Friday, December 19th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $62.17.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.